Landing AI Medical Completes RMB 320 Million Series D Funding Led by Alibaba Health to Build World's First AI-Powered Pathology Screening Cloud Platform

On November 10, Wuhan Landing Medical High-Tech Co., Ltd. (“Landing Medical”), a leading medical AI enterprise in China, officially announced the completion of its RMB 320 million Series D financing round. The round was led by AliHealth, with Yitai Investment participating as a co-investor.China Renaissance served as the exclusive financial advisor for this round of transaction.

Landing Inc. is a high-tech enterprise that provides comprehensive pathology diagnosis solutions leveraging 5G+AI cloud diagnostic technology. With a forward-looking, end-to-end strategic layout, its products and services cover sample preparation and scanning, AI cloud diagnostics, and full-process laboratory quality control. Landing has achieved digital management across the entire industry chain and AI-based cancer cell diagnosis, ensuring accurate and efficient AI pathology diagnostics through a closed-loop data system.

Pathological examination is the gold standard for tumor diagnosis. The domestic pathology market in China is valued at approximately RMB 50 billion, with cytopathology accounting for 75% of this share. However, there is a severe shortage of pathologists in China. While the United States has one pathologist per 11,000 people, China has only one per 136,000 people, meaning the density of pathologists in China is less than 10% of that in the U.S. Furthermore, the distribution of pathologists within China is highly uneven; the vast majority are concentrated in Grade III tertiary hospitals, while registered practicing pathologists in primary healthcare institutions account for less than 1% of the national total. Consequently, the Chinese government encourages multi-site practice for pathologists and leverages AI to enhance the efficiency and accuracy of pathological diagnoses.

Landing Medical focuses on the urgent clinical needs in the field of pathology, pioneering a diversified, multi-tiered commercial closed-loop model integrating “equipment, consumables, and services.” Leveraging its independently developed, globally unique AI-based cancer cell diagnosis technology, Landing Medical has ushered in a new era of automated, intelligent, data-driven, and standardized cervical cancer screening. The company has established an AI-powered cloud platform for cervical cancer screening that enables global expert, capability, and resource sharing. Its AI-based cytology screening technology for cervical cancer has been widely applied across 30 provinces, municipalities, and autonomous regions in China for many years, and has expanded to Belt and Road Initiative countries such as Malaysia, Indonesia, and Pakistan.

Landing Medical High-Tech Co., Ltd. has 12 subsidiaries, has established five large-scale AI laboratories and 67 small- and medium-sized AI laboratories in China, and has completed AI cloud-based diagnostic screening for millions of individuals nationwide, with its products adopted by more than 600 general hospitals. Furthermore, by providing AI-powered diagnostic services via its cloud platform, the company has formed stable collaborations with over 1,000 hospitals and more than 10,000 grassroots sample collection sites at the street and township levels, building a business network that covers the entire country. It is currently delivering high-quality, low-cost cervical cancer screening services to tens of millions of women in China, pioneering the introduction of cervical cancer screening into a new era of AI and big data-enabled cloud diagnostics worldwide.

Sun Xiaorong, Founder and Chairman of Landing MedicalPh.D.He stated, “We extend our gratitude to the investors in this round for their recognition of Landing Medical, and thank all previous investors for their unwavering support along the way. With the successful completion of this financing round, we will leverage our advantages in AI-powered big data cloud diagnostics to establish the world’s first AI-based cytopathological diagnosis cloud for cancer. Aligning with the WHO’s Global Strategy to Accelerate the Elimination of Cervical Cancer by 2030, we have deployed mature AI-driven cervical cancer screening services for ultra-large-scale populations across China, starting from Hubei Province, and have achieved a breakthrough business model that empowers established medical examinations with AI. Landing Medical is expanding its AI-based pathological examination services globally to provide health solutions for women worldwide, with operations already launched in Belt and Road Initiative countries. Meanwhile, by strengthening business synergy with AliHealth and empowered by new resources, we will rapidly expand into the To-C market and primary healthcare clinics, promoting our proven AI-based cytological cervical cancer screening technology to clinical applications for other high-incidence cancers. We will also increase R&D investment and establish the Institute for Clinical Application of AI Cytopathological Diagnostic Technology, aiming to become the global standard-setter for AI-based pathological diagnosis.”

Su Zhiqiang, Executive Director of Alibaba’s Investment DepartmentIt stated: “As a leading enterprise in AI pathology, Wuhan Landing Medical High-Tech Co., Ltd. (Landing) has identified real-world application scenarios for AI after more than ten years of exploration. It has not only developed an AI pathology system based on a large volume of cervical cancer screening samples, thereby alleviating the critical bottleneck caused by the severe shortage of pathologists in China, but also formed detailed solutions and supporting hardware and software for deployment in primary healthcare settings through years of exploration, enabling AI technology and screening service systems to truly reach communities and grassroots levels. As a strategic investor, Alibaba Health will engage in deep business cooperation with Landing in two areas: first, jointly providing high-quality, efficient, end-to-end online and offline cervical cancer screening and testing services to medical institutions in target cities; second, leveraging their respective accumulated resources, channels, and capabilities to jointly develop family-oriented commercial health insurance or cervical cancer screening health protection products.”

Huang Ning, Founding Partner of Daotong InvestmentHe stated, “As the earliest institutional investor in Landing Medical, VCBeat has accompanied and witnessed the maturation and refinement of Landing’s AI-based cervical cancer screening technology. This technology has been deployed at scale by integrating cloud computing and 5G, serving tens of millions of people, achieving successful commercialization ahead of peers, and significantly empowering primary healthcare. The success of the ‘Landing Model’ also demonstrates the great potential of medical AI technologies, while continued capital investment underscores sustained optimism about the sector’s prospects. Innovative medical technologies have always been a key focus for VCBeat. We are highly committed to leveraging our industrial resources and expertise to empower these innovative tech enterprises, acting as a co-pilot to support outstanding entrepreneurs in their growth journey.”

Xie Yijing, Managing Director of China Renaissance, Head of the Healthcare and Life Sciences Group, and Head of the Financial Advisory Division“We are honored to have assisted Wuhan Landing Medical High-Tech Co., Ltd. in completing this milestone private financing transaction. With its world-leading AI-based cancer cell diagnostic platform and technologies, we believe that, supported by this round of financing, the company will continue to leverage its professional team and technological advantages to break through key bottlenecks in pathological diagnosis R&D, achieving further milestones. We will continue to stand by the company as it embarks on a new journey, helping Wuhan Landing Medical High-Tech Co., Ltd. become a global leader in AI-driven pathological diagnostics.”